Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.
2.

Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.

Keane WF, Lyle PA; Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study.

Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S22-5. Review.

PMID:
12612946
3.

Losartan in diabetic nephropathy.

Perico N, Ruggenenti P, Remuzzi G.

Expert Rev Cardiovasc Ther. 2004 Jul;2(4):473-83. Review.

PMID:
15225108
4.

Losartan in diabetic nephropathy.

Carswell CI, Goa KL.

Drugs. 2003;63(4):407-14; discussion 415-6. Review.

PMID:
12558462
5.

Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.

MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD.

Am J Kidney Dis. 2006 Jul;48(1):8-20. Review.

PMID:
16797382
6.

Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade.

Parvanova A, Chiurchiu C, Ruggenenti P, Remuzzi G.

Expert Opin Pharmacother. 2005 Sep;6(11):1931-42. Review.

PMID:
16144512
7.

Angiotensin-converting enzyme inhibition in type I diabetic nephropathy.

Lewis EJ.

Contrib Nephrol. 1996;118:206-13. Review. No abstract available.

PMID:
8744059
8.

[Drug-induced oral ulcerations].

Madinier I, Berry N, Chichmanian RM.

Ann Med Interne (Paris). 2000 Jun;151(4):248-54. Review. French.

PMID:
10922951

Supplemental Content

Support Center